Across TCGA pan-cancer cohorts, OR2T29 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated OR2T29 data layer compared with 5 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher OR2T29 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR2T29 expression acts as an unfavorable survival marker.
COAD are the cancer types where OR2T29 Mutation most reproducibly stratifies survival.